 |
 |

Serotoninergic System in Dementia of the Alzheimer TypeAbnormal Forms of 5-Hydroxytryptophan and Serotonin in Cerebrospinal Fluid
Ladislav Volicer, MD, PhD;
Philip J. Langlais, PhD;
Wayne R. Matson, PhD;
Konrad A. Mark, MD;
Paul H. Gamache, MA
Arch Neurol. 1985;42(12):1158-1161.
Abstract
 |  |
Serotonin (5-HT), its precursor 5-hydroxytryptophan (5-HTP), and its major metabolite 5-hydroxyindoleacetic acid (5-HIAA) were measured in the cerebrospinal fluid (CSF) of 14 patients with dementia of the Alzheimer type (DAT) and in nine controls by high-performance liquid chromatography with a novel multisensor coulometric detection system. Concentrations of both 5-HT and 5-HIAA detected by this system were lower than the concentrations obtained using conventional amperometric detection. This difference was caused by coelution of compounds that could be resolved from 5-HT and 5-HIAA by the multisensor coulometric system. One of the coelution compounds, observed in DAT but not in control CSF, behaved like a partially oxidized 5-HT. A compound behaving like partially oxidized 5-HTP was also observed in DAT CSF. Concentrations of 5-HTP, 5-HT, and 5-HIAA were lower in DAT CSF than in a corresponding fraction of control CSF. These results indicate involvement of the serotoninergic system in DAT and might lead to development of a diagnostic test for DAT.
Author Affiliations
From the Geriatric Research Education Clinical Center, E. N. Rogers Veterans Memorial Hospital (Drs Volicer and Mark) and Environmental Science Associates, Inc (Dr Matson and Mr Gamache), Bedford, Mass; and McLean Hospital (Dr Langlais), Belmont, Mass.
Footnotes
Accepted for publication March 18, 1985.
Reprint requests to E. N. Rogers Memorial Veterans Hospital, GRECC, 200 Springs Rd, Bedford, MA 01730 (Dr Volicer).
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Brain Gangliosides in Dementia of the Alzheimer Type
Crino et al.
Arch Neurol 1989;46:398-401.
ABSTRACT
L-Deprenyl in Alzheimer's Disease: Preliminary Evidence for Behavioral Change With Monoamine Oxidase B Inhibition
Tariot et al.
Arch Gen Psychiatry 1987;44:427-433.
ABSTRACT
|